دورية أكاديمية
Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy.
العنوان: | Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy. |
---|---|
المؤلفون: | Horvat NK; Department of Pediatric Hematology, Oncology and Immunology, Emory University, Atlanta, Georgia, USA., Karpovsky I; Department of Hematology and Oncology, Emory University, Atlanta, Georgia, USA., Phillips M; Department of Hematology and Oncology, Emory University, Atlanta, Georgia, USA., Wyatt MM; Department of Surgery, Department of Microbiology & Immunology, Emory University Winship Cancer Institute, Atlanta, Georgia, USA., Hall MA; Department of Hematology and Oncology, Emory University, Atlanta, Georgia, USA., Herting CJ; Department of Hematology and Oncology, Emory University, Atlanta, Georgia, USA., Hammons J; Department of Hematology and Oncology, Emory University, Atlanta, Georgia, USA., Mahdi Z; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, USA., Moffitt RA; Department of Hematology and Oncology, Emory University, Atlanta, Georgia, USA., Paulos CM; Department of Surgery, Department of Microbiology & Immunology, Emory University Winship Cancer Institute, Atlanta, Georgia, USA gregory.b.lesinski@emory.edu chrystal.mary.paulos@emory.edu., Lesinski GB; Department of Hematology and Oncology, Emory University Winship Cancer Institute, Atlanta, Georgia, USA gregory.b.lesinski@emory.edu chrystal.mary.paulos@emory.edu. |
المصدر: | Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Jan 08; Vol. 12 (1). Date of Electronic Publication: 2024 Jan 08. |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
اللغة: | English |
بيانات الدورية: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
أسماء مطبوعة: | Publication: 2020- : London, United Kingdom : BMJ Publishing Group Ltd. Original Publication: London : BioMed Central, 2013- |
مواضيع طبية MeSH: | Pancreatic Neoplasms*/therapy , Carcinoma, Pancreatic Ductal*/therapy, Humans ; Animals ; Mice ; Mice, Inbred C57BL ; Proto-Oncogene Proteins p21(ras) ; CD8-Positive T-Lymphocytes ; Tumor Suppressor Protein p53 ; Tumor Microenvironment |
مستخلص: | Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor. Prognosis is poor and survival is low in patients diagnosed with this disease, with a survival rate of ~12% at 5 years. Immunotherapy, including adoptive T cell transfer therapy, has not impacted the outcomes in patients with PDAC, due in part to the hostile tumor microenvironment (TME) which limits T cell trafficking and persistence. We posit that murine models serve as useful tools to study the fate of T cell therapy. Currently, genetically engineered mouse models (GEMMs) for PDAC are considered a "gold-standard" as they recapitulate many aspects of human disease. However, these models have limitations, including marked tumor variability across individual mice and the cost of colony maintenance. Methods: Using flow cytometry and immunohistochemistry, we characterized the immunological features and trafficking patterns of adoptively transferred T cells in orthotopic PDAC (C57BL/6) models using two mouse cell lines, KPC-Luc and MT-5, isolated from C57BL/6 KPC-GEMM (Kras LSL-G12D/+ p53 -/- and Kras LSL-G12D/+ p53 LSL-R172H/+ , respectively). Results: The MT-5 orthotopic model best recapitulates the cellular and stromal features of the TME in the PDAC GEMM. In contrast, far more host immune cells infiltrate the KPC-Luc tumors, which have less stroma, although CD4 + and CD8 + T cells were similarly detected in the MT-5 tumors compared with KPC-GEMM in mice. Interestingly, we found that chimeric antigen receptor (CAR) T cells redirected to recognize mesothelin on these tumors that signal via CD3ζ and 41BB (Meso-41BBζ-CAR T cells) infiltrated the tumors of mice bearing stroma-devoid KPC-Luc orthotopic tumors, but not MT-5 tumors. Conclusions: Our data establish for the first time a reproducible and realistic clinical system useful for modeling stroma-rich and stroma-devoid PDAC tumors. These models shall serve an indepth study of how to overcome barriers that limit antitumor activity of adoptively transferred T cells. Competing Interests: Competing interests: GBL has consulted for ProDa Biotech and received compensation. GBL has also received research funding through a sponsored research agreement between Emory University and Merck and Co, Bristol-Myers Squibb, Boehringer Ingelheim, and Vaccinex. CP has received research funding through a sponsored research agreement between the Medical University of South Carolina and Obsidian, Lycera, and ThermoFisher, and is the cofounder of Ares Immunotherapy. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.) |
References: | Front Immunol. 2018 May 14;9:1044. (PMID: 29868007) Cell Rep. 2020 Jan 14;30(2):481-496.e6. (PMID: 31940491) Biosci Rep. 2020 Jul 31;40(7):. (PMID: 32677676) Cancer Discov. 2019 Feb;9(2):282-301. (PMID: 30366930) Proc Natl Acad Sci U S A. 2021 Jun 8;118(23):. (PMID: 34088837) CA Cancer J Clin. 2020 Sep;70(5):375-403. (PMID: 32683683) JCI Insight. 2018 Apr 5;3(7):. (PMID: 29618658) Nat Genet. 2015 Oct;47(10):1168-78. (PMID: 26343385) Nat Commun. 2018 Jul 24;9(1):2897. (PMID: 30042390) Cancer Cell. 2015 Dec 14;28(6):831-833. (PMID: 28843279) Cancers (Basel). 2022 Sep 15;14(18):. (PMID: 36139638) Pancreas. 1995 Nov;11(4):357-64. (PMID: 8532652) Gut. 2013 Jan;62(1):112-20. (PMID: 22466618) Cancer Metastasis Rev. 2021 Sep;40(3):675-689. (PMID: 34591240) Clin Cancer Res. 2016 Jun 15;22(12):2848-54. (PMID: 26813359) Methods Mol Biol. 2013;980:215-23. (PMID: 23359156) Nat Commun. 2017 Apr 27;8:15095. (PMID: 28447602) Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7. (PMID: 24277834) Gut. 2018 Feb;67(2):320-332. (PMID: 27797936) Pancreatology. 2023 Sep;23(6):615-621. (PMID: 37391359) Semin Respir Crit Care Med. 2019 Jun;40(3):347-360. (PMID: 31525810) Nature. 2014 Jul 31;511(7511):543-50. (PMID: 25079552) Cancer Cell. 2021 Apr 12;39(4):548-565.e6. (PMID: 33667385) Front Immunol. 2018 Jul 30;9:1774. (PMID: 30105035) Front Cell Dev Biol. 2021 Jan 11;8:607209. (PMID: 33505964) JCI Insight. 2023 Apr 24;8(8):. (PMID: 36881480) Cancer Cell. 2012 Jun 12;21(6):822-35. (PMID: 22698406) Mol Cancer Ther. 2021 Jan;20(1):150-160. (PMID: 33037138) J Immunother. 2010 Jan;33(1):1-7. (PMID: 19952961) Oncoimmunology. 2015 Jan 22;4(4):e998519. (PMID: 26137414) Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3360-5. (PMID: 19211796) Nat Rev Drug Discov. 2006 Sep;5(9):741-54. (PMID: 16915232) J Transl Med. 2010 Oct 26;8:104. (PMID: 20977748) Annu Rev Pathol. 2023 Jan 24;18:123-148. (PMID: 36130070) Sci Rep. 2017 Dec 4;7(1):16878. (PMID: 29203879) Cancer Res. 2014 Jun 1;74(11):2913-21. (PMID: 24840647) J Clin Oncol. 2019 May 1;37(13):1062-1069. (PMID: 30817250) Cancer Discov. 2020 Feb;10(2):232-253. (PMID: 31699795) J Immunother Cancer. 2019 Jan 25;7(1):19. (PMID: 30683154) Clin Gastroenterol Hepatol. 2008 Oct;6(10):1155-61. (PMID: 18639493) Cancer Res. 2013 Mar 15;73(6):1668-75. (PMID: 23319800) Cancer Lett. 2016 Oct 10;381(1):244-51. (PMID: 26723878) World J Gastroenterol. 2015 Mar 21;21(11):3157-65. (PMID: 25805920) Cancer Res. 2014 Jun 1;74(11):2907-12. (PMID: 24824231) Front Immunol. 2020 Mar 05;11:176. (PMID: 32194541) Cancer Cell. 2020 Dec 14;38(6):788-802. (PMID: 32946773) J Clin Oncol. 2020 Sep 20;38(27):3185-3194. (PMID: 32706635) Commun Biol. 2023 Feb 10;6(1):163. (PMID: 36765128) Cancer Cell. 2017 Aug 14;32(2):185-203.e13. (PMID: 28810144) Nat Commun. 2017 Dec 6;8(1):1961. (PMID: 29213079) Clin Gastroenterol Hepatol. 2009 Nov;7(11 Suppl):S44-7. (PMID: 19896098) Nature. 2012 Sep 27;489(7417):519-25. (PMID: 22960745) |
معلومات مُعتمدة: | R01 CA208514 United States CA NCI NIH HHS; R01 CA175061 United States CA NCI NIH HHS; P30 CA138292 United States CA NCI NIH HHS; R50 CA233186 United States CA NCI NIH HHS; R01 CA275199 United States CA NCI NIH HHS; R01 CA228406 United States CA NCI NIH HHS |
فهرسة مساهمة: | Keywords: CD4-CD8 ratio; T-lymphocytes; receptors, chimeric antigen; receptors, immunologic; tumor microenvironment |
المشرفين على المادة: | EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)) 0 (Tumor Suppressor Protein p53) |
تواريخ الأحداث: | Date Created: 20240108 Date Completed: 20240110 Latest Revision: 20240315 |
رمز التحديث: | 20240315 |
مُعرف محوري في PubMed: | PMC10806555 |
DOI: | 10.1136/jitc-2023-008086 |
PMID: | 38191243 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2051-1426 |
---|---|
DOI: | 10.1136/jitc-2023-008086 |